Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 2767Carcinoma, Non-Small-Cell Lung 2265Prostatic Neoplasms 1427Colorectal Neoplasms 1295Neoplasms 1260Multiple Myeloma 1086Lung Neoplasms 1049Neoplasm Metastasis 995Leukemia, Myeloid, Acute 985Lymphoma 900Melanoma 864Pancreatic Neoplasms 818Ovarian Neoplasms 805Carcinoma, Hepatocellular 782Stomach Neoplasms 753Recurrence 753Leukemia 733Lymphoma, Non-Hodgkin 684Leukemia, Lymphocytic, Chronic, B-Cell 665Squamous Cell Carcinoma of Head and Neck 618Lymphoma, Large B-Cell, Diffuse 617Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Head and Neck Neoplasms 598Brain Neoplasms 593Carcinoma, Renal Cell 587Glioblastoma 573Rectal Neoplasms 565Sarcoma 523Myelodysplastic Syndromes 522Lymphoma, Follicular 516

Interventions

adavosertib 1Paclitaxel 1Gemcitabine 1Carboplatin 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation × Clear all
NCT02272790 2023-10-03

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

AstraZeneca

Phase 2 Completed
95 enrolled 61 charts
Gynecologic

Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡